OVID 241220 5.00P (OVID241220P5000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

OVID241220P5000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 14 09:33 ET · Ratings
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Moomoo NewsNov 14 08:31 ET · Ratings
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
Moomoo NewsNov 13 23:32 ET · Ratings
Ovid Therapeutics: Strategic Developments and Financial Stability Lead to Buy Rating
TipRanksNov 13 22:55 ET · Ratings
Ovid Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 12 09:41 ET · Announcements
Ovid Therapeutics | 8-K: Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
SECNov 12 09:40 ET

Comments

MARKET-TEST-DUMMY

Jul 20 09:27

👀

$Ovid Therapeutics (OVID.US)$

70205719

Jul 12 16:19

$Ovid Therapeutics (OVID.US)$ break 1.17 next week, then fill in the gap sooner.

TraderKen26

Jul 1 19:11

$Ovid Therapeutics (OVID.US)$ why the super dump?

Jaguar8

Jul 1 13:07

NEWS

$Ovid Therapeutics (OVID.US)$
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
Ovid Therapeutics and Graviton Bioscience announced positive Phase 1 trial results for their OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). The trial met its primary objective by demonstrating a favorable safety and to...

Jaguar8

Jun 17 06:40

NEWS

$Ovid Therapeutics (OVID.US)$
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Ovid Therapeutics reported on Takeda's Phase 3 study results for soticlestat, a treatment for Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). The Skyline study in DS narrowly missed its primary endpoint but showed significant effects in secondary endpoints with p-values ≤ 0.008. The Skyway study in LGS missed its primary endpoint. Soticlestat had a favorabl...